Cargando…

The Discovery of Small Allosteric and Active Site Inhibitors of the SARS-CoV-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation

The main protease enzyme (M(pro)) of SARS-CoV-2 is one of the most promising targets for COVID-19 treatment. Accordingly, in this work, a structure-based virtual screening of 3.8 million ligand libraries was carried out. After rigorous filtering, docking, and post screening assessments, 78 compounds...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahgoub, Radwa E., Mohamed, Feda E., Alzyoud, Lara, Ali, Bassam R., Ferreira, Juliana, Rabeh, Wael M., AlNeyadi, Shaikha S., Atatreh, Noor, Ghattas, Mohammad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572942/ https://www.ncbi.nlm.nih.gov/pubmed/36235244 http://dx.doi.org/10.3390/molecules27196710

Ejemplares similares

Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents
por: Alzyoud, Lara, et al.
Publicado: (2022)

The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines
por: Ghemrawi, Rose, et al.
Publicado: (2022)

Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening
por: Atatreh, Noor, et al.
Publicado: (2019)

Controlled Release of Pyrimidine Compound Using Polymeric Coated ZIF-8 Metal-Organic Framework as Glucagon-Like Peptide-1 Receptor Agonist Carrier
por: AlNeyadi, Shaikha S., et al.
Publicado: (2020)

Structure-based assessment and druggability classification of protein–protein interaction sites
por: Alzyoud, Lara, et al.
Publicado: (2022)

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
por: Ferreira, Juliana C., et al.
Publicado: (2020)

Molecular Modelling Study and Antibacterial Evaluation of Diphenylmethane Derivatives as Potential FabI Inhibitors
por: Hasan, Shaima, et al.
Publicado: (2023)

Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
por: Ferreira, Juliana C., et al.
Publicado: (2022)

Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening
por: Atatreh, Noor, et al.
Publicado: (2018)

Allosteric Hotspots in the Main Protease of SARS-CoV-2
por: Strömich, Léonie, et al.
Publicado: (2022)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS‐CoV‐2 protease 3CLpro
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Chanarin-Dorfman syndrome treatment with acitretin
por: AlNeyadi, Reem, et al.
Publicado: (2022)

Druggability analysis and classification of protein tyrosine phosphatase active sites
por: Ghattas, Mohammad A, et al.
Publicado: (2016)

Myocardial dysfunction associated with diabetic ketoacidosis in a 5-year-old girl
por: Halloum, Amjad, et al.
Publicado: (2019)

An extended conformation of SARS-CoV-2 main protease reveals allosteric targets
por: Sun, Zengchao, et al.
Publicado: (2022)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
por: Guo, Sheng, et al.
Publicado: (2021)

Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization
por: Mercorelli, Beatrice, et al.
Publicado: (2022)

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
por: Günther, Sebastian, et al.
Publicado: (2021)

Broad-Spectrum Allosteric Inhibition of Herpesvirus Proteases
por: Gable, Jonathan E., et al.
Publicado: (2014)

Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
por: El‐Baba, Tarick J., et al.
Publicado: (2020)

Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis
por: Verma, Shalja, et al.
Publicado: (2021)

pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity
por: Al Adem, Kenana, et al.
Publicado: (2022)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Discovery of genistein derivatives as potential SARS-CoV-2 main protease inhibitors by virtual screening, molecular dynamics simulations and ADMET analysis
por: Liu, Jiawei, et al.
Publicado: (2022)

Allosteric Modulation of the Main Protease (M(Pro)) of SARS-CoV-2 by Casticin—Insights from Molecular Dynamics Simulations
por: Mensah, Jehoshaphat Oppong, et al.
Publicado: (2022)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease
por: Marinho, Emanuelle Machado, et al.
Publicado: (2020)

Virtual screening of peptides with high affinity for SARS-CoV-2 main protease
por: Porto, William Farias
Publicado: (2021)

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease
por: Deodato, Davide, et al.
Publicado: (2022)

Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddings
por: Dong, Jie, et al.
Publicado: (2022)

An Allosteric Modulator of HIV-1 Protease Shows Equipotent Inhibition of Wild-Type and Drug-Resistant Proteases
por: Ung, Peter M.-U., et al.
Publicado: (2014)

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
por: Jiménez-Alberto, Alicia, et al.
Publicado: (2020)

Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Screening, molecular simulation & in silico kinetics of virtually designed covid-19 main protease inhibitors
por: Aleissa, Mohammed S., et al.
Publicado: (2022)

A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease
por: Hernández González, Jorge E., et al.
Publicado: (2022)

In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor
por: Wen, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tug914mbad3sfak4pib7iuj556